A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

January 12, 2035

Study Completion Date

January 12, 2035

Conditions

Huntington Disease

Interventions

GENETIC

SPK-10001

Specified dose on specified days

OTHER

Placebo Surgery Control

Placebo Surgery procedure for SPK-10001

Trial Locations (3)

RECRUITING

Ohio State University, Columbus

RECRUITING

University of Cincinnati/Cincinnati Children's Hospital, Cincinnati

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

lead

Spark Therapeutics, Inc.

INDUSTRY

NCT06826612 - A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease | Biotech Hunter | Biotech Hunter